Condition
Esophageal Neoplasms
ClinicalTrials.gov condition label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 24 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
24 shownA Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791 · 2025-10-22
RECRUITINGA Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601 · 2025-08-06
RECRUITINGSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)NCT06469944 · 2024-09-20
RECRUITINGDiagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis TechniquesNCT07035587 · 2024-08-21
RECRUITINGSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)NCT06445972 · 2024-08-07
RECRUITINGA Phase I/II Trial of UCB4594 in Participants With Advanced CancerNCT06380816 · 2024-07-09
RECRUITINGHTL0039732 in Participants With Advanced Solid TumoursNCT05944237 · 2023-08-02
RECRUITINGEffects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With CancerNCT05875870 · 2023-07-24
RECRUITINGLuso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences(ES-LCCE-UDFM)NCT06862479 · 2025-01-01
ENROLLING_BY_INVITATION[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid TumorsNCT05619016 · 2022-11-23
UNKNOWNMK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)NCT05007106 · 2021-09-16
COMPLETEDA Study of SGN-STNV in Advanced Solid TumorsNCT04665921 · 2021-01-18
TERMINATEDContinuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesNCT02859415 · 2019-08-08
TERMINATEDThe Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage INCT02845479 · 2018-12-07
COMPLETEDA Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid TumorsNCT03261947 · 2017-10-25
COMPLETEDFirst-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)NCT03189719 · 2017-07-25
COMPLETEDTumor Hypoxia With HX4 PET in Several DiseasesNCT02584400 · 2016-05-01
TERMINATEDAnalysis of Risk Factors of Postoperative Pulmonary Infection in Patients With Esophageal CancerNCT05740852 · 2016-01-01
COMPLETEDNutritional Route In Esophageal Resection Trial IINCT02378948 · 2015-10-01
COMPLETEDImpact of Perioperative Physical Activity on Postoperative Pulmonary Complications and Quality of Life Among Esophageal Cancer PatientsNCT03231462 · 2015-03-06
UNKNOWNThe Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic SurgeryNCT01267305 · 2011-01-01
COMPLETEDEndoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal HypertensionNCT04994548 · 2005-01-01
COMPLETEDDepsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumNCT00094978 · 2004-10-25
TERMINATEDMagnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the LiverNCT00041808 · 2001-07-01
COMPLETEDCommon interventions
PembrolizumabBIOLOGICAL3CapecitabineDRUG2CisplatinDRUG2OxaliplatinDRUG2PaclitaxelDRUG2[68Ga]Ga-ABY-025 PETDIAGNOSTIC_TEST15-FluorouracilDRUG15-Fluorouracil (5-FU)DRUG15-FUDRUG1BevacizumabDRUG1Biopsy and analysis of HER2 expressionDIAGNOSTIC_TEST1CarboplatinDRUG1ChemotherapyPROCEDURE1Daylight exposure combine walkingBEHAVIORAL1DepsipeptideDRUG1DocetaxelDRUG1Endoscopic management of fistulas with stents or vacum therapyPROCEDURE1Endosocpic resection of early esophageal tumorPROCEDURE1Flavopiridol (alvocidib)DRUG1FondaparinuxDRUG1GemcitabineDRUG1HER3-DXdBIOLOGICAL1HTL0039732 CapsulesDRUG1HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusionDRUG1Injection with the hypoxia tracer [18F]HX4,DRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Merck Sharp & Dohme LLC
4
Cancer Research UK
2
Eli Lilly and Company
2
National Cancer Institute (NCI)
2
Catharina Ziekenhuis Eindhoven
1
Central Hospital, Nancy, France
1
FeRx
1
Karolinska University Hospital
1
Maastricht Radiation Oncology
1
Millennium Pharmaceuticals, Inc.
1
Samsung Medical Center
1
Seagen Inc.
1
Shanghai Zhongshan Hospital
1
Taipei Veterans General Hospital, Taiwan
1
The Canadian College of Naturopathic Medicine
1
Trial status mix
COMPLETED9
RECRUITING8
TERMINATED4
UNKNOWN2
ENROLLING_BY_INVITATION1
Phase mix
PHASE110
PHASE210
NA3
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.